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Background/Aims: We aimed to evaluate survival 
time and prognostic factors in patients with advanced 
unresectable cholangiocarcinoma who have not re-
ceived surgery, chemotherapy, or radiotherapy. Me-
thods: A total of 1,377 patients, who were diagnosed 
with primary cholangiocarcinoma between 1996 and 
2002, were reviewed retrospectively according to the 
following inclusion criteria: histologically proven pri-
mary adenocarcinoma arising from the bile-duct epi-
thelium, advanced unresectable stages, no severe co-
morbidity that can affect survival time, and no history 
of surgery, chemotherapy, or radiotherapy. Results: 
Of the 1,377 cases reviewed, 330 patients complied 
with the inclusion criteria and were thus eligible to 
participate in this study; 203 had intrahepatic chol-
angiocarcinoma and 127 had hilar cholangiocarcinoma. 
The overall survival time of the entire cohort (n=330) 
was median 3.9 months (range; 0.2 to 67.1). The sur-
vival time was significantly shorter in the intrahepatic 
cholangiocarcinoma group (3.0±5.3 months) than in 
the hilar cholangiocarcinoma group (5.9±10.1 months; 
Kaplan-Meier survival analysis). Multivariate analysis 
revealed that distant metastasis was a poor prog-
nostic factor for intrahepatic cholangiocarcinoma (p＜ 
0.001), baseline serum albumin ＞3.0 g/dL was a fa-
vorable prognostic factor (p=0.02), and baseline serum 
carcinoembryonic antigen level ＞30 ng/mL was a 
poor prognostic factor for hilar cholangiocarcinoma 
(p=0.01).  Conclusions: The median survival of ad-
vanced unresectable cholangiocarcinoma is dismal.   
(Gut and Liver 2009;3:298-305)
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INTRODUCTION
  Cholangiocarcinoma is the second most common pri-
mary hepatobiliary cancer, after hepatocellular carcinoma.
1 
Although the incidence of the entity is lower in countries 
such as the USA and Europe compared with the East, the 
incidence is steadily rising in the West.
2-5 
  While surgical resection remains the only curative treat-
ment, most patients are far advanced at presentation 
which leads to high mortality rates. Radiotherapy and 
systemic chemotherapy have been evaluated in unresec-
table cholangiocarcinoma, but have failed to show sat-
isfactory results.
6-13 Recently photodynamic therapy has 
been evaluated in hopes to confront this intractable 
disease.
14 Due to the restricted number of patients in-
cluded in the trial, however, benefits have been debatable 
and there have been limitations in generalizing the 
results. 
  The aim of this study was to evaluate the “natural his-
tory”, which is the outcome from the time of diagnosis to 
death without therapeutic intervention, of cholangiocar-
cinoma. To our knowledge, this is the first large-scale 
study that investigated the survival data of patients with 
advanced cholangiocarcinoma who did not receive ther-
apeutic interventions including surgery, chemotherapy or 
radiotherapy. Knowing the natural history, specifically the Park JH, et al: Natural History of Advanced Cholangiocarcinoma   299
Fig. 1. Study population. Between 1996 and 2002, 1,377 patients were diagnosed with cholangiocarcinoma at our institute; 330 of
these patients complied with the inclusion criteria and could thus be included in the study. 
*Although some cases were clinically operable, surgery was not performed due to the patients’ refusal.
survival, of cholangiocarcinoma is important for rational 
treatment recommendations. We hope our results regard-
ing survival will be used as a reference standard in the 
outcome assessment of therapeutic maneuvers for this 
challenging disease.
MATERIALS AND METHODS
  Between 1996 and 2002, a total of 1,377 patients coded 
by the disease code of International Classification of 
Disease (ICD-10) with primary cholangiocarcinoma were 
managed at our institute, a 2,700-bed tertiary referral uni-
versity hospital with a dedicated center for cholangiocar-
cinoma. After obtaining approval from the institutional 
review board to review the patient records for the out-
l i n e d  s t u d y ,  w e  r e v i e w e d  m e d i c a l  c h a r t s  t o  i d e n t i f y  p a -
tients for retrospective analysis according to the following 
inclusion criteria; histologically proven primary adenocar-
c i n o m a  a r i s i n g  f r o m  b i l e  d u c t  e p i t h e l i u m ,  a d v a n c e d  u n -
resectable stages, no comorbidity that can affect survival 
(e.g., severe cardiac, pulmonary or renal disease), and no 
history of surgery, chemotherapy or radiotherapy. The 
time and cause of death of those patients were identified 
from medical records of our institute or data of mortality 
offered by National Statistical Office.
  We excluded gallbladder cancer, metastatic cancer and 
cases diagnosed on radiographic appearance without patho-
logic proof in order to rule out any malignant appearing 
benign biliary strictures. Unresectability was determined 
with preoperative evaluation or open biopsy and the fol-
lowing clinical conditions were considered to be un-
resectable;
6,15-18 involvement of bilateral secondary radical 
hepatic ducts, invasion of main portal vein or proper hep-
atic artery, atrophy of one hepatic lobe with contralateral 
vascular invasion, atrophy of one hepatic lobe with con-
tralateral tumor extension to secondary biliary confluence, 
invasion of secondary biliary confluence on one lobe and 
contralateral vascular invasion, or distant metastasis. We 
excluded patients who received chemotherapy, radio-
therapy, or any surgical intervention (palliative or cura-
tive) for cholangiocarcinoma. For example, 3 patients 
with Bismuth type I hilar cholangiocarcinoma could not 300   Gut and Liver, Vol. 3, No. 4, December 2009
Table 1. Basal Characteristics of Advanced Unresectable Cho-
langiocarcinoma
Intrahepatic Hilar 
cholangiocar- cholangiocar-
cinoma cinoma 
(n=203) (n=127)
Age (years)   57±10.3   62±10.1
Sex
M a l e  ( n )     1 3 2      8 4
F e m a l e  ( n )      7 1      4 3
Survival (months,    3.0±5.3   5.9±10.1
 median±SD)
Extent of disease (n)
TNM staging* Bismuth - 
 Corlette 
 classification
SI   1 BI  3
SII   1 BII  6
SIII  88 BIIIA 23
SIV 113 BIIIB 19
BIV 76
D i s t a n t       1 1 3      2 4
 metastasis (n)
Macroscopic growth
 patterns
†
 (n)
Mass-forming     187
Periductal infiltrating      15
Intraductal       1
Biliary drainage (n)
P T B D      5 2     1 2 1
E R B D       4       0
N o  d r a i n a g e     1 4 7       6
Baseline Lab (Mean±SD)
‡
Blood WBC  9833±4153.9 9294.5±5929
 (×10
3
/mm
3
)
Albumin (g/dL)   3.3±0.7    3.2±0.6
AST (IU/L)  73.7±90  108.4±114.8
ALT (IU/L)  58.2±71.4  104.9±115.6
ALP (IU/L) 469.4±438.8  771.6±676.9
Total bilirubin      4±6.4   15.3±41.1
 (mg/dL)
CEA (ng/mL) 105.9±333.2   16.2±32.4
CA 19-9 (u/mL)  8420±36930.8 2571.8±6986.6
PTBD, percutaneous transhepatic biliary drainage; ERBD, 
endoscopic retrograde biliary drainage. 
*AJCC 6th edition; 
†
The classification proposed by the Liver 
Cancer Study Group of Japan
20
; 
‡
Checked
 
before biliary drai-
nage.
undergo surgical operation due to major vessel involve-
ment of cholangiocarcinoma. And 6 patients with Bismuth 
type II hilar cholangiocarcinoma could not undergo surgi-
cal operation due to distant metastasis, major vessel in-
volvement or previous hepatic lobectomy. In the cases 
without any treatment, the patient and his or her family 
elected to not pursue any aggressive palliation therapy in-
cluding chemotherapy or radiotherapy after full ex-
planation of risks and benefits of various treatment 
modalities. However, patients who received only non-
surgical biliary drainage were included. We also excluded 
extrahepatic cholangiocarcinoma patients because most 
cases were candidates to surgical therapy.
  Univariate analysis was performed with the Kaplan-Meier 
method and log-rank test. Significant factors on univariate 
analysis were then evaluated by multivariate analysis us-
ing the Cox proportional hazards model. p values less 
than 0.05 were considered significant.
RESULTS
1. Demographics and clinical characteristics of 
overall cholangiocarcinoma
  Of the 1,377 cases reviewed, 330 patients with un-
resectable, advanced cholangiocarcinoma met our eligi-
bility criteria: 203 intrahepatic and 127 hilar chol-
angiocarcinoma patients (Fig. 1). Median follow-up peri-
ods were 0.9 months (0.1-24 months) for intrahepatic 
cholangiocarcinoma patients and 2.7 months (0.1-24 
months) for hilar cholangiocarcinoma patients. They con-
sisted of 216 men (65.5%) and 114 women (34.5%) with 
a mean age of 59±10.5 years (mean±SD; range, 25 to 
86). One hundred and thirty six (41.2%) patients had 
distant metastasis (Table 1). 
  As a risk factor for the development of cholangiocar-
cinoma, 27 patients had Clonorchis sinensis infection, 
whereas only one patient had primary sclerosing cho-
langitis. Fifty-three patients had hepatolithiasis. Five pa-
tients had choledochal cyst and twenty eight patients had 
history of chronic viral hepatitis. 
2. Clinical features of intrahepatic cholangiocar-
cinoma
  Two hundred and three patients were diagnosed as in-
trahepatic cholangiocarcinoma: 132 men (65%) and 71 
women (35%), with an age of 57±10.3 years (mean±SD; 
range, 29 to 82). Among them, 113 (55.7%) patients had 
distant metastasis. Stage distribution by TNM staging sys-
tem was stage I in 1 (0.5%) patient, stage II in 1 (0.5%), 
stage III in 88 (43.3%) and stage IV in 113 (55.7%). By 
using the classification scheme for primary liver cancer 
proposed by the Liver Cancer Study Group of Japan,
11,19,20 
macroscopic growth patterns of patients with intrahepatic 
cholangiocarcinoma were classified as mass-forming type 
in 187 (92.1%) patients, periductal infiltrating type in 15 
(7.4%) patients and intraductal type in 1 patient (0.5%), 
respectively (Table 1). Park JH, et al: Natural History of Advanced Cholangiocarcinoma   301
Table 2. Disease Extent of Advanced Unresectable Cholangio-
carcinoma and Its Impact on Survival
Intrahepatic 
cholangiocarcinoma 
TNM staging*
Hilar cholangiocarcinoma
Bismuth-Corlette 
classification
Median 
n
survival
Median 
n
survival
SI   1 6.0 BI  3 9.9
SII   1 7.4 BII  6 2.6
SIII  88 4.4 BIIIA 23 6
SIV 113 2.5 BIIIB 19 6
BIV 76 5.7
Univariate analysis  Univariate analysis 
(p-value); 0.004 (p-value); 0.5
*AJCC 6th edition.
Table 3. Variables Associated with Survival of Advanced Unresectable Intrahepatic Cholangiocarcinoma
Median survival p-value  p-value  Odds ratio Exp(B)
Variabables 
(month) (univariate) (multivariate) (95% CI)
Metastasis/Localized disease 2.5/4.0  ＜0.001 ＜0.001 1.7 (1.3-2.3)
Albumin  ＞3.0/≤3.0 (g/dL) 3.8/2.3    0.005   0.02 0.7 (0.5-0.9)
TNM staging    *   0.004
CEA  ＞30 (ng/mL)   3.0   0.84
CA 19-9 ＞150 (U/mL)   3.0   0.44
Male   3.0   0.45
Age  ＞60 years   3.8   0.39
Macroscopic  pattern
†
  3.0   0.76
No biliary drainage   3.0   0.77
Leukocytosis
‡
  2.4   0.09
AST＞40 (IU/L)   3.0   0.38
ALT＞4 0  ( I U / L )   3 . 0   0 . 2
ALP＞120 (IU/L)   3.0   0.16
Bilirubin  ＞10 (mg/dL)   2.9   0.53
*Median survival according to TNM stage is described in Table 2; 
†
Mass-forming growth pattern according to the classification 
proposed by the Liver Cancer Study Group of Japan
20
; 
‡
WBC＞10,000 (×10
3
/mm
3
).
Fig. 2. Survival graphs of advanced unresectable cholangio-
carcinoma. The overall median survival time for all cholan-
giocarcinoma patients (n=330) was 3.9 months. The median 
survival time was shorter for those with intrahepatic cho-
langiocarcinoma (3 months) than for those with hilar cho-
langiocarcinoma (5.9 months; p＜0.001).
3. Clinical features of hilar cholangiocarcinoma 
  One hundred and twenty seven patients were diagnosed 
as hilar cholangiocarcinoma: 84 men (66.1%) and 43 wom-
en (33.9%), with an age of 62±10.1 years (mean±SD; 
range, 25 to 86). The extent of intraductal spread by the 
Bismuth-Corlette classification system
21 was Bismuth type 
I in 3 (2.4%) patients, Bismuth type II in 6 (4.7%), 
Bismuth type IIIA in 23 (18.1%), Bismuth type IIIB in 19 
(15%), and Bismuth type IV in 76 (59.8%), respectively 
(Table 1).
4. Survival time
  Median survival time of overall cholangiocarcinoma was 
3.9±7.8 months (median±SD; range, 0.2 to 67.1); 3±5.3 
months (0.2 to 37.7) for intrahepatic cholangiocarcinoma 
and 5.9±10.1 months (0.6 to 67.1) for hilar cholangio-
carcinoma. By Kaplan-Meier survival analysis, intrahepatic 
cholangiocarcinoma patients had shorter survival than hi-
lar cholangiocarcinoma (p＜0.001) (Fig. 2).
According to TNM staging in intrahepatic cholangio-
carcinoma, median survival time of each stage revealed 6 
months in stage I, 7.4 months in stage II, 4.4 months in 
stage IIIA, 3.6 months in stage IIIC and 2.5 months in 
stage IV, respectively. According to the Bismuth-Corlette 302   Gut and Liver, Vol. 3, No. 4, December 2009
Table 4. Variables Associated with Survival of Advanced Unresectable Hilar Cholangiocarcinoma
Median survival  p-value  p-value Odds ratio Exp(B)
Variabables
(month) (univariate) (multivariate) (95% CI)
CEA  ＞30/≤30 (ng/mL) 3.5/5.8  0.008 0.01 2.3 (1.2-4.5)
Albumin  ＞3.0/≤3.0 (g/dL) 6.7/3.5 0.02
Bilirubin  ＞10/≤10 (mg/dL) 4.3/6.8 0.018
CA 19-9＞150 (U/mL)   5.4 0.05
Metastasis   3.5 0.1
Bismuth-Corlette classification    * 0.5
Male   6 0.2
Age  ＞60 years   5.7 0.94
Leukocytosis
†
  4 . 6 0 . 2 9
AST  ＞40 (IU/L)   5.4 0.21
ALT  ＞40 (IU/L)   5.4 0.1
ALP  ＞120 (IU/L)   5.7 0.31
*Median survival according to Bismuth-Corlette classification is described in Table 2; 
†
WBC＞10,000 (×10
3
/mm
3
).
classification system for hilar cholangiocarcinoma, median 
survival time of each stage identified 9.9 months in 
Bismuth type I, 2.6 months in Bismuth type II, 6 months 
in Bismuth type IIIA, 6 months in Bismuth type IIIB and 
5.7 months in Bismuth type IV, respectively (Table 2).
5. Prognostic factors  
1) Intrahepatic cholangiocarcinoma
  Univariate analysis showed that patients with baseline 
(before biliary decompression) serum albumin level ＞3.0 
g/dL (p=0.005) and lower TNM staging (p=0.004) had 
significantly longer survival time, whereas patients with 
distant metastasis had significantly shorter survival time 
(p＜0.001) (Tables 2 and 3). 
  By multivariate analysis, distant metastasis was a poor 
prognostic factor predicting shorter survival (p＜0.001; 
odds ratio [OR], 1.7; 95% confidence interval [CI], 
1.3-2.3) and baseline serum albumin level＞3.0 g/dL was 
an independent favorable prognostic factor (p＜0.02; OR, 
0.7; 95% CI; 0.5-0.9) (Table 3).
2) Hilar cholangiocarcinoma
  By univariate analysis, patients with baseline serum al-
bumin level＞3.0 g/dL (p=0.02) had longer survival, 
whereas patients with baseline serum total bilirubin leve
l＞10.0 mg/dL (p=0.01), serum CEA level ＞30 ng/mL 
(p=0.008) had shorter survival. Disease extent by 
Bismuth-Corlette classification showed no correlation 
with survival (p=0.5) (Tables 2 and 4). 
    Multivariate analysis showed serum CEA level＞30 
ng/mL (p=0.01; OR, 2.3; 95% CI, 1.2-4.5) was an in-
dependent predictor of shorter survival (Table 4).
DISCUSSION
    During the last few years, some emerging chemo-
therapeutic regimens and endoscopic interventions have 
been evaluated for the patients with advanced un-
resectable cholangiocarcinoma. In these studies, patients 
with advanced unresectable cholangiocarcinoma were re-
p o r t e d  t o  h a v e  a  w i d e  r a n g e  o f  s u r v i v a l  t i m e  f r o m  5 7  
days to 8.7 months.
7,14,22-26 One recent trial
14 reported 
that the endoscopic application of photodynamic therapy 
to malignant strictures prolonged median survival time of 
unresectable hilar cholangiocarcinoma when compared to 
those treated with nonsurgical biliary drainage alone. 
Compared to our study (median survival, 5.9 months), 
however, the nonsurgical biliary drainage alone group as a 
control displayed shorter survival (median survival, 98 
days). One plausible explanation for different survival 
time between two studies may be differences in biliary 
drainage route used for relief of obstructive jaundice. 
While percutaneous biliary drainage (PTBD) was the sole 
approach for patients with hilar cholangiocarcinoma in 
our study, most patients received endoscopic retrograde 
biliary drainage (ERBD) in a previous study.
14 In a recent 
study,
26 PTBD showed significant higher rate of successful 
biliary decompression and lower level of procedure-related 
cholangitis in patients with advanced Bismuth type III or 
IV hilar cholangiocarcinoma, compared to ERBD. Com-
pared to endoscopic drainage, PTBD may be more effec-
tive in achieving earlier recognition of drainage tube mal-
function and preventing subsequent attacks of cholangitis 
and biliary sepsis, which may lead to longer survival.
  As for intrahepatic cholangiocarcinoma, Shaib et al.
25  re-
p o r t e d  a  m e d i a n  s u r v i v a l  o f  5 7  d a y s  i n  p a t i e n t s  n o t  r e -
ceiving any palliative treatment, which was shorter than Park JH, et al: Natural History of Advanced Cholangiocarcinoma   303
that (median 90 days) of our study. The authors ad-
dressed limitations of the analysis that only aged 65 years 
or older patients were included in the study and the in-
formation such as TNM staging was not recorded in 
37.5% of enrolled patients due to the limitation of mul-
ti-institutional study.
25 Differences in survival between 
two studies may stem from intrinsic factors including di-
verse ethnicity of patient population. Underlying disease 
may be another important contributing factor. While pri-
mary sclerosing cholangitis is often associated with chol-
angiocarcinoma in Western countries, it is relatively rare-
ly seen in Asian countries.
27 Actually, in our series of 330 
patients of cholangiocarcinoma, we identified only one 
case of primary sclerosing cholangitis. Considering the 
fact that patients with primary sclerosing cholangitis are 
usually associated with chronic liver dysfunction and of-
ten progress to biliary cirrhosis,
28 this difference may af-
fect survival time.
  A few prognostic factors for survival were noted in our 
study. Serum albumin level above 3.0 g/dL was a favor-
able prognostic factor in both univariate and multivariate 
analysis for intrahepatic cholangiocarcinoma; whereas, it 
showed statistical significance only in univariate analysis 
for hilar cholangiocarcinoma. This factor has previously 
been attended by Nakeeb et al.
9 who reported that pre-
operative serum albumin level was associated with longer 
survival in the surgical outcome of patients with chol-
angiocarcinoma. On the other hand, serum bilirubin level 
above 10 mg/dL have been reported to be associated with 
poor surgical outcome in patients with hilar cholangio-
carcinoma on multivariate analysis;
29,30 however, this fac-
tor was only a poor prognostic factor in univariate analy-
sis of our patients with unresectable conditions (Table 4). 
Tumor markers disclosed some prognostic value in our 
series. For hilar cholangiocarcinoma, baseline serum CEA 
level above 30 ng/mL was an independent poor prog-
nostic factor. However, CA 19-9 above 150 U/mL was 
poor prognostic factor in only univariate analysis (Table 
4). Although some tumor markers have been investigated 
to diagnose cholangiocarcinoma
31-35 and predict post-oper-
ative prognosis or recurrence,
36-38 to our knowledge this is 
the first study to investigate the prognostic capability of 
tumor markers in cholangiocarcinoma patients without 
any surgery, chemotherapy or radiotherapy.
  In our study, multivariate analysis showed that distant 
metastasis was the only independently poor prognostic 
factor for intrahepatic cholangiocarcinoma (p＜0.001), 
whereas TNM staging for intrahepatic cholangiocarcinoma 
showed significant relationship with survival time (p= 
0.004) only on univariate analysis. Interestingly, Bismuth- 
Corlette classification were not related to survival time of 
hilar cholangiocarcinoma (p=0.5). It may be because 
Bismuth-Corlette classification relies on intraductal tumor 
extension of cholangiocarcinoma, which cannot provide 
overall staging information. 
  Several limitations of our study deserve comment. Our 
study was retrospective and, therefore, holds the usual 
limitation of such design. We could not follow up many 
cases to the time of death, so we investigated data of 
mortality offered by National Statistical Office for many 
cases. Unfortunately the data did not include a immediate 
cause of death, either. Therefore, we could not evaluate 
the immediate causes of death exactly. In addition, cut-off 
values of tumor markers were determined arbitrarily be-
cause it was not possible to calculate the Receiver 
Operating Characteristic (ROC) curve due to the death of 
all patients and the range of tumor markers from the pre-
vious studies
35-38 was too wide to determine appropriate 
reference values. Despite these limitations, this is the 
largest study to date regarding this topic and all data 
were obtained from a single institute making data inter-
pretation more reliable. Selection bias may also have been 
introduced into the results, as the review was confined to 
histologically proven cases. However, this was inevitable 
as some benign biliary disease including IgG4-associated 
cholangitis can mimic cholangiocarcinoma radiographi-
cally.
39 In East Asia, recurrent pyogenic cholangitis asso-
c i a t e d  w i t h  b i l e  d u c t  s t o n e s  o r  l i v e r  f l u k e  i s  n o t  u n -
common
40,41 and in this setting, we cannot definitely rule 
out benign biliary disease on the basis of clinical findings 
without pathological confirmation. 
  In conclusion, the median survival of unresectable chol-
angiocarcinoma was dismal. In terms of survival time, in-
trahepatic cholangiocarcinoma patients showed poorer 
prognosis than hilar cholangiocarcinoma patients. Distant 
metastasis and baseline serum albumin level were in-
dependent prognostic factors for intrahepatic cholangio-
carcinoma, while serum CEA level for hilar cholangio-
carcinoma. 
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